Literature DB >> 33136563

The Clinical Relevance of Manometric Esophagogastric Junction Outflow Obstruction Can Be Determined Using Rapid Drink Challenge and Solid Swallows.

Santosh Sanagapalli1,2,3, Joshua McGuire2, Rupert W Leong4, Kalp Patel2, Amanda Raeburn2, Humayra Abdul-Razakq2, Andrew Plumb2, Matthew Banks2, Rehan Haidry2, Laurence Lovat2, Vinay Sehgal2, David Graham2, Sarmed S Sami2, Rami Sweis2.   

Abstract

INTRODUCTION: Esophagogastric junction outflow obstruction (EGJOO) defined on high-resolution esophageal manometry (HRM) poses a management dilemma given marked variability in clinical manifestations. We hypothesized that findings from provocative testing (rapid drink challenge and solid swallows) could determine the clinical relevance of EGJOO.
METHODS: In a retrospective cohort study, we included consecutive subjects between May 2016 and January 2020 with EGJOO. Standard HRM with 5-mL water swallows was followed by provocative testing. Barium esophagography findings were obtained. Cases with structural obstruction were separated from functional EGJOO, with the latter categorized as symptom-positive or symptom-negative. Only symptom-positive subjects were considered for achalasia-type therapies. Sensitivity and specificity for clinically relevant EGJOO during 5-mL water swallows, provocative testing, and barium were calculated.
RESULTS: Of the 121 EGJOO cases, 76% had dysphagia and 25% had holdup on barium. Ninety-seven cases (84%) were defined as functional EGJOO. Symptom-positive EGJOO subjects were more likely to demonstrate abnormal motility and pressurization patterns and to reproduce symptoms during provocative testing, but not with 5-mL water swallows. Twenty-nine (30%) functional EGJOO subjects underwent achalasia-type therapy, with symptomatic response in 26 (90%). Forty-eight (49%) functional EGJOO cases were managed conservatively, with symptom remission in 78%. Although specificity was similar, provocative testing demonstrated superior sensitivity in identifying treatment responders from spontaneously remitting EGJOO (85%) compared with both 5-mL water swallows (54%; P < 0.01) and barium esophagography (54%; P = 0.02). DISCUSSION: Provocative testing during HRM is highly accurate in identifying clinically relevant EGJOO that benefits from therapy and should be routinely performed as part of the manometric protocol.
Copyright © 2020 by The American College of Gastroenterology.

Entities:  

Year:  2021        PMID: 33136563     DOI: 10.14309/ajg.0000000000000988

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  9 in total

1.  Assessment and management of dysphagia and achalasia.

Authors:  Amir Mari; Rami Sweis
Journal:  Clin Med (Lond)       Date:  2021-03       Impact factor: 2.659

2.  British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults.

Authors:  Anjan Dhar; Hasan N Haboubi; Stephen E Attwood; Marcus K H Auth; Jason M Dunn; Rami Sweis; Danielle Morris; Jenny Epstein; Marco R Novelli; Hannah Hunter; Amanda Cordell; Sharon Hall; Jamal O Hayat; Kapil Kapur; Andrew Robert Moore; Carol Read; Sarmed S Sami; Paul J Turner; Nigel J Trudgill
Journal:  Gut       Date:  2022-05-23       Impact factor: 31.793

Review 3.  Esophageal Motility Disorders: Current Approach to Diagnostics and Therapeutics.

Authors:  Dhyanesh A Patel; Rena Yadlapati; Michael F Vaezi
Journal:  Gastroenterology       Date:  2022-02-25       Impact factor: 33.883

4.  Response to Sanagapalli and Sweis.

Authors:  Dustin A Carlson; John E Pandolfino
Journal:  Am J Gastroenterol       Date:  2022-02-01       Impact factor: 12.045

Review 5.  Esophageal motility disorders on high-resolution manometry: Chicago classification version 4.0©.

Authors:  Rena Yadlapati; Peter J Kahrilas; Mark R Fox; Albert J Bredenoord; C Prakash Gyawali; Sabine Roman; Arash Babaei; Ravinder K Mittal; Nathalie Rommel; Edoardo Savarino; Daniel Sifrim; André Smout; Michael F Vaezi; Frank Zerbib; Junichi Akiyama; Shobna Bhatia; Serhat Bor; Dustin A Carlson; Joan W Chen; Daniel Cisternas; Charles Cock; Enrique Coss-Adame; Nicola de Bortoli; Claudia Defilippi; Ronnie Fass; Uday C Ghoshal; Sutep Gonlachanvit; Albis Hani; Geoffrey S Hebbard; Kee Wook Jung; Philip Katz; David A Katzka; Abraham Khan; Geoffrey Paul Kohn; Adriana Lazarescu; Johannes Lengliner; Sumeet K Mittal; Taher Omari; Moo In Park; Roberto Penagini; Daniel Pohl; Joel E Richter; Jordi Serra; Rami Sweis; Jan Tack; Roger P Tatum; Radu Tutuian; Marcelo F Vela; Reuben K Wong; Justin C Wu; Yinglian Xiao; John E Pandolfino
Journal:  Neurogastroenterol Motil       Date:  2021-01       Impact factor: 3.598

Review 6.  Advances and caveats in modern achalasia management.

Authors:  Marcella Pesce; Rami Sweis
Journal:  Ther Adv Chronic Dis       Date:  2021-03-12       Impact factor: 5.091

7.  Changes in the esophagogastric junction outflow obstruction manometric feature based on the Chicago Classification updates.

Authors:  Yue-Yuan Li; Wen-Ting Lu; Jian-Xiang Liu; Li-Hong Wu; Meng Chen; Hong-Mei Jiao
Journal:  World J Gastroenterol       Date:  2022-08-14       Impact factor: 5.374

8.  Chicago classification v4.0 protocol improves specificity and accuracy of diagnosis of oesophagogastric junction outflow obstruction.

Authors:  Pierfrancesco Visaggi; Matteo Ghisa; Giulio Del Corso; Federica Baiano Svizzero; Lucia Mariani; Salvatore Tolone; Marzio Frazzoni; Andrea Buda; Massimo Bellini; Vincenzo Savarino; Roberto Penagini; C Prakash Gyawali; Edoardo V Savarino; Nicola de Bortoli
Journal:  Aliment Pharmacol Ther       Date:  2022-06-25       Impact factor: 9.524

Review 9.  Chicago classification version 4.0© technical review: Update on standard high-resolution manometry protocol for the assessment of esophageal motility.

Authors:  Mark R Fox; Rami Sweis; Rena Yadlapati; John Pandolfino; Albis Hani; Claudia Defilippi; Tack Jan; Nathalie Rommel
Journal:  Neurogastroenterol Motil       Date:  2021-03-17       Impact factor: 3.598

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.